https://www.selleckchem.com/pr....oducts/itacitinib-in
8%, 27.8%, and 0.0%, respectively. PSM analysis showed no difference in OS between patients who underwent ALPPS and those that received TACE [P=0.178, Barcelona Clinic Liver Cancer (BCLC) stage A-C patients; P=0.241, BCLC stage B and C patients]. ALPPS is a safe and effective treatment option for unresectable HBV-related HCC. However, for HBV-related intermediate and advanced HCC patients, ALPPS may not be superior to TACE. ALPPS is a safe and effective treatment option for unresectable HBV-related HCC. However, for HBV-rel
Like
Comment
Share
